Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has launched its once-daily Seroquel extended-release tablets for the acute treatment of the depressive episodes associated with bipolar disorder and the manic and mixed episodes associated with bipolar I disorder, as well as the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
Subscribe to our email newsletter
Seroquel extended-release (XR) tablet is also now available in two new strengths, 50mg and 150mg. Once-daily Seroquel XR is the only FDA-approved medication for the treatment of acute depressive, manic and mixed episodes of bipolar disorder, the company said.
Seroquel XR is now available in 50mg, 150mg, 200mg, 300mg, and 400mg tablet strengths. Seroquel XR is also approved for the acute and maintenance treatment of schizophrenia.
Arthur Lazarus, senior director of clinical development at AstraZeneca, said: When symptomatic, people with bipolar disorder experience depressive symptoms more than three times longer than manic symptoms, and this may interfere with daily activities. The approval of Seroquel XR for the treatment of bipolar disorder provides patients with the only medication that has been proven to treat the acute depressive, manic and mixed episodes of bipolar disorder.
AstraZeneca is an international healthcare business engaged in the research, development, manufacturing and marketing of prescription medicines and is a supplier for healthcare services. AstraZeneca is the producer of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.